MedTrace Logo

Omega 3 Fatty Acid Trial

NCT00586222 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2012-01-25

No results posted yet for this study

Summary

This study is being done to detect the metabolic changes that Omega 3 fatty acid treatment has on the brain and to find out whether magnetic resonance spectroscopy (MRS) scan can detect metabolic differences between bipolar patients and healthy control participants.

Conditions

  • Omega-3 Fatty Acids
  • Pediatric Bipolar Disorder
  • Adolescent Bipolar Disorder
  • Magnetic Resonance Spectroscopy Imaging

Interventions

DIETARY_SUPPLEMENT

Omega-3 Fatty Acid

600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.

OTHER

Placebo

placebo pill of the same size, color, and shape as the dietary supplement.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Sencan S Unal, M.D. P · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00586222 on ClinicalTrials.gov